Alnylam Pharma (ALNY) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $159.89 --0%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
OGN, GSAT, FULC, More
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
OGN, GSAT, FULC, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.08 better than the analyst estimate of ($1.66). Revenue for the quarter came in at $125.9 million versus the consensus estimate of $120.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi raises Keurig Dr Pepper price target to $40
- ArcBest (ARCB) Tops Q3 EPS by 14c
- AudioCodes Ltd. (AUDC) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
